Lamberts SW, Bakker WH, Reubi JC, Krenning EP (1990a) Treatment with Sandostatin and in vivo

localization of tumors with radiolabeled somatostatin analogs. Metabolism 39(9):152–155

Lamberts SW, Reubi JC, Bakker WH, Krenning EP (1990b) Somatostatin receptor imaging with

123I-Tyr3-octreotide. Zeitschrift fur Gastroenterologie 28:20

Matthay KK, Yanik G, Messina J, Quach A, Huberty J, Cheng SC, Veatch J, Goldsby R, Brophy P,

Kersun LS, Hawkins RA (2007) Phase II study on the effect of disease sites, age, and prior

therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblas-

toma. J Clin Oncol 25(9):1054–1060

Miao Y, Quinn TP (2008) Peptide-targeted radionuclide therapy for melanoma. Crit Rev Oncol

Hematol 67:213–228

Moadel RM, Nguyen AV, Lin EY, Lu P, Mani J, Blaufox MD, Pollard JW, Dadachova E (2003)

Positron emission tomography agent 2-deoxy-2-[18 F] fluoro-D-glucose has a therapeutic

potential in breast cancer. Breast Cancer Res 5(6):1–7

Morgenstern A, Apostolidis C, Kratochwil C et al (2018) An overview of targeted alpha therapy

with 225Actinium and 213Bismuth. Curr Radiopharm 11:200–208

Nuhn P, DeBono JS, Fizazi K, Freedland SJ, Grilli M, Kantoff PW et al (2019) Update on systemic

prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the

era of precision oncology. Eur Urol 75:88–99. https://doi.org/10.1016/j.eururo.2018.03.028

Parihar AS, Basher RK, Rana N et al (2018a) Incidental meningioma on ⁶⁸Ga-DOTANOC

positron-emission tomography. Indian. J Nucl Med 33(2):182

Parihar AS, Ga A, Sood K et al (2018b) Incidental detection of synchronous lung melanoma on

18F-FDG PET/CT in a patient with parotid gland myoepithelial carcinoma. Clin Nucl Med

43(4):e127–e129

Parihar AS, Mittal BR, Sood A, et al (2018c) ⁶⁸Ga-prostate-specific membrane antigen PET/CT and

18F-FDG PET/CT of primary signet ring cell breast adenocarcinoma. Clin Nucl Med 43(11):

e414–e416

Parihar AS, Mittal BR, Vadi SK et al (2018d) (18)F-FDG PET/CT detects metastatic renal cell

carcinoma masquerading as primary breast malignancy. Nucl Med Mol Imaging 52(6):475–478.

https://doi.org/10.1007/s13139-018-0553-6

Parihar AS, Mittal BR, Vadi SK et al (2018e) ¹⁸F-FDG PET/CT in isolated primary extraskeletal

osteosarcoma. Clin Nucl Med 43(12):e463–e464

Parihar AS, Mittal BR, Vadi SK et al (2018f) Ectopic Cushing syndrome (ECS): ⁶⁸Ga-DOTANOC

PET/CT localizes the site of ectopic adrenocorticotropic hormone production. Clin Nucl Med

43(10):769–770. https://doi.org/10.1097/RLU.0000000000002217

Parihar AS, Mittal BR, Vadi SK et al (2018g) Groove pancreatitis masquerading as pancreatic

carcinoma-detected on (18)F-FDG PET/CT. Nucl Med Mol Imaging 52(6):473–474. https://doi.

org/10.1007/s13139-018-0552-7

Parihar AS, Singh H, Kumar R et al (2018h) Pancreatic malignancy or not?: role of ¹⁸F-FDG

PET/CT in solving the diagnostic dilemma and evaluating treatment response. Clin Nucl Med

43(4):e115–e117. https://doi.org/10.1097/RLU.0000000000001989

Parihar AS, Sood A, Kumar R et al (2018i) Novel use of ¹⁷⁷Lu-DOTA-RGD2 in treatment of ⁶⁸Ga-

DOTA-RGD2-avid lesions in papillary thyroid cancer with TENIS. Eur J Nucl Med Mol

Imaging 45(10):1836–1837

Parihar AS, Vadi SK, Kumar R et al (2018j) ⁶⁸Ga-DOTA-Exendin PET/CT for detection of

Insulinoma in a patient with persistent hyperinsulinemic hypoglycemia. Clin Nucl Med 43(8):

e285–e286

Parihar AS, Vadi SK, Mittal BR et al (2018k) ⁶⁸Ga-PSMA-HBED-CC-avid synchronous urinary

bladder paraganglioma in a patient with metastatic prostate carcinoma. Clin Nucl Med 43(9):

e329–e330

Parihar AS, Mittal BR, Kumar R et al (2020a) ⁶⁸Ga-DOTA-RGD2 PET/CT in radioiodine (¹³¹I)

refractory thyroid cancer – prospective comparison of diagnostic accuracy with ¹⁸F-FDG

PET/CT and evaluation towards potential theranostics. Thyroid 30(4):557–67

108

B. Singh et al.